

Dierk Thomas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5118431/publications.pdf>

Version: 2024-02-01

205
papers

5,765
citations

71061

41
h-index

118793

62
g-index

210
all docs

210
docs citations

210
times ranked

5914
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of atrial fibrillation pattern on outcomes after left atrial appendage closure: lessons from the prospective LAARGE registry. <i>Clinical Research in Cardiology</i> , 2022, 111, 511-521.	1.5	4
2	Sudden cardiac death while waiting: do we need the wearable cardioverter-defibrillator?. <i>Clinical Research in Cardiology</i> , 2022, 111, 1189-1197.	1.5	2
3	Cryoballoon pulmonary vein isolation-mediated rise of sinus rate in patients with paroxysmal atrial fibrillation. <i>Clinical Research in Cardiology</i> , 2021, 110, 124-135.	1.5	4
4	Prospective multicentric validation of a novel prediction model for paroxysmal atrial fibrillation. <i>Clinical Research in Cardiology</i> , 2021, 110, 868-876.	1.5	4
5	HDAC2-dependent remodeling of KCa2.2 (KCNN2) and KCa2.3 (KCNN3) K ⁺ channels in atrial fibrillation with concomitant heart failure. <i>Life Sciences</i> , 2021, 266, 118892.	2.0	14
6	Safety and patient-reported outcomes in index ablation versus repeat ablation in atrial fibrillation: insights from the German Ablation Registry. <i>Clinical Research in Cardiology</i> , 2021, 110, 841-850.	1.5	8
7	Predictors and Prognostic Implications of Cardiac Arrhythmias in Patients Hospitalized for COVID-19. <i>Journal of Clinical Medicine</i> , 2021, 10, 133.	1.0	39
8	Epigenetic regulation of cardiac electrophysiology in atrial fibrillation: HDAC2 determines action potential duration and suppresses NRSF in cardiomyocytes. <i>Basic Research in Cardiology</i> , 2021, 116, 13.	2.5	9
9	Trigger-Specific Remodeling of KCa2 Potassium Channels in Models of Atrial Fibrillation. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 579-590.	0.4	5
10	Differential regulation of K _{Ca} 2.1 (<i>KCNN1</i>) K ⁺ channel expression by histone deacetylases in atrial fibrillation with concomitant heart failure. <i>Physiological Reports</i> , 2021, 9, e14835.	0.7	9
11	ESC working group on cardiac cellular electrophysiology position paper: relevance, opportunities, and limitations of experimental models for cardiac electrophysiology research. <i>Europace</i> , 2021, 23, 1795-1814.	0.7	24
12	Newly acquired complete right bundle branch block early after heart transplantation is associated with lower survival. <i>ESC Heart Failure</i> , 2021, 8, 3737-3747.	1.4	6
13	Atrial fibrillation before heart transplantation is a risk factor for post-transplant atrial fibrillation and mortality. <i>ESC Heart Failure</i> , 2021, 8, 4265-4277.	1.4	7
14	Histone deacetylase 2-dependent ventricular electrical remodeling in a porcine model of early heart failure. <i>Life Sciences</i> , 2021, 281, 119769.	2.0	4
15	Dynamic risk assessment to improve quality of care in patients with atrial fibrillation: the 7th AFNET/EHRA Consensus Conference. <i>Europace</i> , 2021, 23, 329-344.	0.7	38
16	Electrical Ventricular Remodeling in Dilated Cardiomyopathy. <i>Cells</i> , 2021, 10, 2767.	1.8	6
17	Symptomatic arrhythmias after catheter ablation of atrioventricular nodal reentrant tachycardia (AVNRT): results from the German Ablation Registry. <i>Clinical Research in Cardiology</i> , 2020, 109, 858-868.	1.5	0
18	Combined amiodarone and digitalis therapy before heart transplantation is associated with increased post-transplant mortality. <i>ESC Heart Failure</i> , 2020, 7, 2082-2092.	1.4	5

#	ARTICLE	IF	CITATIONS
19	Ablation of Atrial Fibrillation in Patients with Hypertension—An Analysis from the German Ablation Registry. <i>Journal of Clinical Medicine</i> , 2020, 9, 2402.	1.0	4
20	Electrophysiological effects of non-vitamin K antagonist oral anticoagulants on atrial repolarizing potassium channels. <i>Europace</i> , 2020, 22, 1409-1418.	0.7	2
21	Pharmacologic TWIK-Related Acid-Sensitive K ⁺ Channel (TASK-1) Potassium Channel Inhibitor A293 Facilitates Acute Cardioversion of Paroxysmal Atrial Fibrillation in a Porcine Large Animal Model. <i>Journal of the American Heart Association</i> , 2020, 9, e015751.	1.6	21
22	Five-year results of heart rate control with ivabradine or metoprolol succinate in patients after heart transplantation. <i>Clinical Research in Cardiology</i> , 2020, , 1.	1.5	3
23	Pulmonary vein isolation treats symptomatic AF in a patient with Lamin A/C mutation: case report and review of the literature. <i>Clinical Research in Cardiology</i> , 2020, 109, 1070-1075.	1.5	1
24	Elevated pre-transplant pulmonary vascular resistance is associated with early post-transplant atrial fibrillation and mortality. <i>ESC Heart Failure</i> , 2020, 7, 177-188.	1.4	18
25	Quantitative Efficacy and Fate of Mesenchymal Stromal Cells Targeted to Cardiac Sites by Radiofrequency Catheter Ablation. <i>Cell Transplantation</i> , 2020, 29, 096368972091423.	1.2	0
26	Inhibition of cardiac Kv4.3 (Ito) channel isoforms by class I antiarrhythmic drugs lidocaine and mexiletine. <i>European Journal of Pharmacology</i> , 2020, 880, 173159.	1.7	5
27	<i>In vivo</i> cardiac pacemaker function of differentiated human mesenchymal stem cells from adipose tissue transplanted into porcine hearts. <i>World Journal of Stem Cells</i> , 2020, 12, 1133-1151.	1.3	3
28	Butterfly and reverse butterfly: usefulness of a resistance band to provoke exercise-induced arrhythmias during catheter ablation in a patient refractory to pharmacological stimulation. <i>Clinical Research in Cardiology</i> , 2019, 108, 110-113.	1.5	0
29	Cardiac K2P13.1 (THIK-1) two-pore-domain K ⁺ channels: Pharmacological regulation and remodeling in atrial fibrillation. <i>Progress in Biophysics and Molecular Biology</i> , 2019, 144, 128-138.	1.4	3
30	Pacemaker cell characteristics of differentiated and HCN4-transduced human mesenchymal stem cells. <i>Life Sciences</i> , 2019, 232, 116620.	2.0	9
31	Augmentation of myocardial If dysregulates calcium homeostasis and causes adverse cardiac remodeling. <i>Nature Communications</i> , 2019, 10, 3295.	5.8	27
32	N-Glycosylation of TREK-1/hK2P2.1 Two-Pore-Domain Potassium (K2P) Channels. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5193.	1.8	12
33	The C-terminal HCN4 variant P883R alters channel properties and acts as genetic modifier of atrial fibrillation and structural heart disease. <i>Biochemical and Biophysical Research Communications</i> , 2019, 519, 141-147.	1.0	13
34	Genetic Ablation of TASK-1 (Tandem of P Domains in a Weak Inward Rectifying K ⁺ Channel) Suppresses Atrial Fibrillation and Prevents Electrical Remodeling. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2019, 12, e007465.	2.1	25
35	ANK2 functionally interacts with KCNH2 aggravating long QT syndrome in a double mutation carrier. <i>Biochemical and Biophysical Research Communications</i> , 2019, 512, 845-851.	1.0	5
36	Digitalis therapy is associated with higher comorbidities and poorer prognosis in patients undergoing ablation of atrial arrhythmias: data from the German Ablation Registry. <i>Clinical Research in Cardiology</i> , 2019, 108, 1083-1092.	1.5	6

#	ARTICLE	IF	CITATIONS
37	Risk factors and survival of patients with permanent pacemaker implantation after heart transplantation. <i>Journal of Thoracic Disease</i> , 2019, 11, 5440-5452.	0.6	19
38	Remote vs. conventional navigation for catheter ablation of atrial fibrillation: insights from prospective registry data. <i>Clinical Research in Cardiology</i> , 2019, 108, 298-308.	1.5	9
39	Cloning and characterization of zebrafish K2P13.1 (THIK-1) two-pore-domain K ⁺ channels. <i>Journal of Molecular and Cellular Cardiology</i> , 2019, 126, 96-104.	0.9	4
40	German Cardiac Society Working Group on Cellular Electrophysiology state-of-the-art paper: impact of molecular mechanisms on clinical arrhythmia management. <i>Clinical Research in Cardiology</i> , 2019, 108, 577-599.	1.5	27
41	New Targets for Old Drugs: Cardiac Glycosides Inhibit Atrial-Specific K _{2P} 3.1 (TASK-1) Channels. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 365, 614-623.	1.3	12
42	Report on the Ion Channel Symposium. <i>Herzschrittmachertherapie Und Elektrophysiologie</i> , 2018, 29, 4-13.	0.3	1
43	Updated Survey on Interventional Electrophysiology. <i>JACC: Clinical Electrophysiology</i> , 2018, 4, 820-827.	1.3	31
44	Ion Channel Dysfunctions in Dilated Cardiomyopathy in Limb-Girdle Muscular Dystrophy. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, e001893.	1.6	40
45	Successful localization and ablation of a Mahaim potential using a high-resolution mapping catheter after a failed conventional ablation attempt. <i>Clinical Research in Cardiology</i> , 2018, 107, 607-610.	1.5	2
46	Control of cardiac chronotropic function in patients after heart transplantation: effects of ivabradine and metoprolol succinate on resting heart rate in the denervated heart. <i>Clinical Research in Cardiology</i> , 2018, 107, 138-147.	1.5	18
47	Novel approach to discriminate left bundle branch block from nonspecific intraventricular conduction delay using pacing-induced functional left bundle branch block. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2018, 53, 347-355.	0.6	2
48	Channelopathies in Heart Disease. <i>Cardiac and Vascular Biology</i> , 2018, , 1-5.	0.2	0
49	Reduced Na ⁺ Current in Native Cardiomyocytes of a Brugada Syndrome Patient Associated With β -2-Syntrophin Mutation. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, e002263.	1.6	11
50	COPD in patients after heart transplantation is associated with a prolonged hospital stay, early posttransplant atrial fibrillation, and impaired posttransplant survival. <i>Clinical Epidemiology</i> , 2018, Volume 10, 1359-1369.	1.5	14
51	Cardiovascular pharmacology of K2P17.1 (TASK-4, TALK-2) two-pore-domain K ⁺ channels. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2018, 391, 1119-1131.	1.4	7
52	Role of ion channels in heart failure and channelopathies. <i>Biophysical Reviews</i> , 2018, 10, 1097-1106.	1.5	45
53	Use of the wearable cardioverter-defibrillator (WCD) and WCD-based remote rhythm monitoring in a real-life patient cohort. <i>Heart and Vessels</i> , 2018, 33, 1390-1402.	0.5	13
54	Identification and functional characterization of zebrafish K _{2P} 17.1 (TASK-4, TALK-2) two-pore-domain K ⁺ channels. <i>European Journal of Pharmacology</i> , 2018, 831, 94-102.	1.7	3

#	ARTICLE	IF	CITATIONS
55	Inhibition of Histone Deacetylases Induces K ⁺ Channel Remodeling and Action Potential Prolongation in HL-1 Atrial Cardiomyocytes. <i>Cellular Physiology and Biochemistry</i> , 2018, 49, 65-77.	1.1	14
56	Atrial fibrillation and heart failure-associated remodeling of two-pore-domain potassium (K ₂ P) channels in murine disease models: focus on TASK-1. <i>Basic Research in Cardiology</i> , 2018, 113, 27.	2.5	33
57	Inverse remodelling of K ₂ P _{3.1} K ⁺ channel expression and action potential duration in left ventricular dysfunction and atrial fibrillation: implications for patient-specific antiarrhythmic drug therapy. <i>European Heart Journal</i> , 2017, 38, ehw559.	1.0	74
58	TREK-1 (K ₂ P _{2.1}) K ⁺ channels are suppressed in patients with atrial fibrillation and heart failure and provide therapeutic targets for rhythm control. <i>Basic Research in Cardiology</i> , 2017, 112, 8.	2.5	43
59	A Distinct Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1209-1210.	1.2	8
60	Dual Mechanism for Inhibition of Inwardly Rectifying Kir _{2.x} Channels by Quinidine Involving Direct Pore Block and PIP ₂ -interference. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017, 361, 209-218.	1.3	6
61	Role of plasma membrane-associated AKAPs for the regulation of cardiac IK ₁ current by protein kinase A. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2017, 390, 493-503.	1.4	4
62	Inhibition of inwardly rectifying Kir _{2.x} channels by the novel anti-cancer agent gambogic acid depends on both pore block and PIP ₂ interference. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2017, 390, 701-710.	1.4	10
63	Stretch-activated two-pore-domain (K ₂ P) potassium channels in the heart: Focus on atrial fibrillation and heart failure. <i>Progress in Biophysics and Molecular Biology</i> , 2017, 130, 233-243.	1.4	37
64	Atrial myofibroblast activation and connective tissue formation in a porcine model of atrial fibrillation and reduced left ventricular function. <i>Life Sciences</i> , 2017, 181, 1-8.	2.0	16
65	Long-term symptom improvement and patient satisfaction following catheter ablation of supraventricular tachycardia: insights from the German ablation registry. <i>European Heart Journal</i> , 2017, 38, 1317-1326.	1.0	68
66	Risk for life-threatening arrhythmia in newly diagnosed peripartum cardiomyopathy with low ejection fraction: a German multi-centre analysis. <i>Clinical Research in Cardiology</i> , 2017, 106, 582-589.	1.5	67
67	ECG-based 4D-dose reconstruction of cardiac arrhythmia ablation with carbon ion beams: application in a porcine model. <i>Physics in Medicine and Biology</i> , 2017, 62, 6869-6883.	1.6	14
68	Immobilization for carbon ion beam ablation of cardiac structures in a porcine model. <i>Physica Medica</i> , 2017, 43, 134-139.	0.4	4
69	Comparison of posttransplant outcomes in patients with no, acute, or chronic amiodarone use before heart transplantation. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 1827-1837.	2.0	18
70	Fully digital data processing during cardiovascular implantable electronic device follow-up in a high-volume tertiary center. <i>European Journal of Medical Research</i> , 2017, 22, 41.	0.9	0
71	Subtype-specific differentiation of cardiac pacemaker cell clusters from human induced pluripotent stem cells. <i>Stem Cell Research and Therapy</i> , 2017, 8, 229.	2.4	46
72	Chronic digitalis therapy in patients before heart transplantation is an independent risk factor for increased posttransplant mortality. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 1399-1407.	0.9	7

#	ARTICLE	IF	CITATIONS
73	The influence of surgical technique on early posttransplant atrial fibrillation — comparison of biatrial, bicaval, and total orthotopic heart transplantation. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 287-297.	0.9	23
74	Long-term use of amiodarone before heart transplantation significantly reduces early post-transplant atrial fibrillation and is not associated with increased mortality after heart transplantation. <i>Drug Design, Development and Therapy</i> , 2016, 10, 677.	2.0	21
75	Inhibition of Cardiac Kir Current (IK1) by Protein Kinase C Critically Depends on PKC β^2 and Kir2.2. <i>PLoS ONE</i> , 2016, 11, e0156181.	1.1	9
76	Feasibility Study on Cardiac Arrhythmia Ablation Using High-Energy Heavy Ion Beams. <i>Scientific Reports</i> , 2016, 6, 38895.	1.6	92
77	Dilation of the Aorta Ascendens Forms Part of the Clinical Spectrum of HCN4 Mutations. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2313-2315.	1.2	25
78	Catheter ablation of atrial fibrillation in patients with concomitant sinus bradycardiaâ€”Insights from the German Ablation Registry. <i>Journal of Electrocardiology</i> , 2016, 49, 117-123.	0.4	2
79	Catheter ablation of atrial fibrillation and atrial flutter in patients with diabetes mellitus: Who benefits and who does not? Data from the German ablation registry. <i>International Journal of Cardiology</i> , 2016, 214, 25-30.	0.8	22
80	Novel ion channel targets in atrial fibrillation. <i>Expert Opinion on Therapeutic Targets</i> , 2016, 20, 947-958.	1.5	31
81	Antiarrhythmic gene therapy â€” will biologics replace catheters, drugs and devices?. <i>European Journal of Pharmacology</i> , 2016, 791, 264-273.	1.7	7
82	Renal denervation for treatment of ventricular arrhythmias: data from an International Multicenter Registry. <i>Clinical Research in Cardiology</i> , 2016, 105, 873-879.	1.5	67
83	Response to Letter Regarding Article, â€œUpregulation of K _{2P} 3.1 K ⁺ Current Causes Action Potential Shortening in Patients With Chronic Atrial Fibrillationâ€. <i>Circulation</i> , 2016, 133, e440-1.	1.6	5
84	Therapeutic targeting of two-pore-domain potassium (K2P) channels in the cardiovascular system. <i>Clinical Science</i> , 2016, 130, 643-650.	1.8	43
85	Sex-related outcome of atrial fibrillation ablation: Insights from the German Ablation Registry. <i>Heart Rhythm</i> , 2016, 13, 1837-1844.	0.3	77
86	Inherited Arrhythmias: Of Channels, Currents, and Swimming. <i>Biophysical Journal</i> , 2016, 110, 1017-1022.	0.2	2
87	A Simple, Non-Invasive Score to Predict Paroxysmal Atrial Fibrillation. <i>PLoS ONE</i> , 2016, 11, e0163621.	1.1	5
88	Efficacy, High Procedural Safety And Rapid Optimization Of Cryoballoon Atrial Fibrillation Ablation In The Hands Of A New Operator. <i>Journal of Atrial Fibrillation</i> , 2016, 8, 1341.	0.5	3
89	Differential Effects of Antiarrhythmic Drugs Vernakalant and Flecainide on Human Two-Pore-Domain K ⁺ Channels. <i>Biophysical Journal</i> , 2015, 108, 110a.	0.2	0
90	Anesthetic drug midazolam inhibits cardiac human ether-â€”go-go-related gene channels: mode of action. <i>Drug Design, Development and Therapy</i> , 2015, 9, 867.	2.0	4

#	ARTICLE	IF	CITATIONS
91	Atrial Fibrillation Complicated by Heart Failure Induces Distinct Remodeling of Calcium Cycling Proteins. PLoS ONE, 2015, 10, e0116395.	1.1	36
92	Prevalence of Intracardiac Thrombi Under Phenprocoumon, Direct Oral Anticoagulants (Dabigatran) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 Journal of Cardiology, 2015, 115, 635-640.	0.7	35
93	Expression and function of Kv1.1 potassium channels in human atria from patients with atrial fibrillation. Basic Research in Cardiology, 2015, 110, 505.	2.5	35
94	Rescue renal sympathetic denervation in a patient with ventricular electrical storm refractory to endo- and epicardial catheter ablation. Clinical Research in Cardiology, 2015, 104, 79-84.	1.5	25
95	Rescue renal sympathetic denervation in a patient with ventricular electrical storm refractory to endo- and epicardial catheter ablation: response to comments by Huang et al.. Clinical Research in Cardiology, 2015, 104, 194-195.	1.5	6
96	Effects of β -blocker therapy on electrocardiographic and echocardiographic characteristics of left ventricular noncompaction. Clinical Research in Cardiology, 2015, 104, 241-249.	1.5	18
97	Upregulation of $K_{v2.1}$ Current Causes Action Potential Shortening in Patients With Chronic Atrial Fibrillation. Circulation, 2015, 132, 82-92.	1.6	172
98	Parameter Estimation of Ion Current Formulations Requires Hybrid Optimization Approach to Be Both Accurate and Reliable. Frontiers in Bioengineering and Biotechnology, 2015, 3, 209.	2.0	17
99	Inhibition of cardiac Kv1.5 potassium current by the anesthetic midazolam: mode of action. Drug Design, Development and Therapy, 2014, 8, 2263.	2.0	7
100	Herg K ⁺ Channel-Dependent Apoptosis and Cell Cycle Arrest in Human Glioblastoma Cells. PLoS ONE, 2014, 9, e88164.	1.1	46
101	Analysis of malignancies in patients after heart transplantation with subsequent immunosuppressive therapy. Drug Design, Development and Therapy, 2014, 9, 93.	2.0	27
102	Class III antiarrhythmic drug dronedarone inhibits cardiac inwardly rectifying Kir2.1 channels through binding at residue E224. Naunyn-Schmiedeberg's Archives of Pharmacology, 2014, 387, 1153-1161.	1.4	6
103	The Symptom Complex of Familial Sinus Node Dysfunction and Myocardial Noncompaction Is Associated With Mutations in the HCN4 Channel. Journal of the American College of Cardiology, 2014, 64, 757-767.	1.2	128
104	Modulation of $K_{v2.1}$ and $K_{v10.1}$ channel sensitivity to carvedilol by alternative mRNA translation initiation. British Journal of Pharmacology, 2014, 171, 5182-5194.	2.7	34
105	Cardiac expression and atrial fibrillation-associated remodeling of K2P2.1 (TREK-1) K ⁺ channels in a porcine model. Life Sciences, 2014, 97, 107-115.	2.0	38
106	Modulation of K2P K ⁺ Leak Channel Sensitivity to Carvedilol by Alternative MRNA Translation Initiation. Biophysical Journal, 2014, 106, 120a.	0.2	0
107	Inhibition of cardiac two-pore-domain K ⁺ (K2P) channels by the antiarrhythmic drug vernakalant " Comparison with flecainide. European Journal of Pharmacology, 2014, 724, 51-57.	1.7	19
108	Isoenzyme-specific regulation of cardiac Kv1.5/Kv β 1.2 ion channel complex by protein kinase C: central role of PKC β II. Naunyn-Schmiedeberg's Archives of Pharmacology, 2014, 387, 469-476.	1.4	5

#	ARTICLE	IF	CITATIONS
109	Functional characterization of zebrafish K2P18.1 (TRESK) two-pore-domain K ⁺ channels. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2014, 387, 291-300.	1.4	22
110	Induced KCNQ1 autoimmunity accelerates cardiac repolarization in rabbits: Potential significance in arrhythmogenesis and antiarrhythmic therapy. <i>Heart Rhythm</i> , 2014, 11, 2092-2100.	0.3	25
111	Vernakalant activates human cardiac K2P17.1 background K ⁺ channels. <i>Biochemical and Biophysical Research Communications</i> , 2014, 451, 415-420.	1.0	8
112	Cloning, functional characterization, and remodeling of K2P3.1 (TASK-1) potassium channels in a porcine model of atrial fibrillation and heart failure. <i>Heart Rhythm</i> , 2014, 11, 1798-1805.	0.3	47
113	Inhibition of cardiac two-pore-domain K ⁺ (K2P) channels – an emerging antiarrhythmic concept. <i>European Journal of Pharmacology</i> , 2014, 738, 250-255.	1.7	34
114	The influence of endoscopic vein harvesting on outcomes after coronary bypass grafting: a meta-analysis of 267 525 patients. <i>European Journal of Cardio-thoracic Surgery</i> , 2013, 44, 980-989.	0.6	63
115	Altered HCN4 channel C-linker interaction is associated with familial tachycardia-bradycardia syndrome and atrial fibrillation. <i>European Heart Journal</i> , 2013, 34, 2768-2775.	1.0	84
116	Analysis of Zolpidem-Induced Long Qt Syndrome in Recombinant hERG Channels and Stem Cell Derived Human Cardiomyocytes. <i>Biophysical Journal</i> , 2013, 104, 298a.	0.2	0
117	Study Design of the Man and Machine Trial: A Prospective International Controlled Noninferiority Trial Comparing Manual with Robotic Catheter Ablation for Treatment of Atrial Fibrillation. <i>Journal of Cardiovascular Electrophysiology</i> , 2013, 24, 40-46.	0.8	17
118	Class I antiarrhythmic drugs inhibit human cardiac two-pore-domain K ⁺ (K2P) channels. <i>European Journal of Pharmacology</i> , 2013, 721, 237-248.	1.7	28
119	Anti-KCNQ1 K ⁺ channel autoantibodies increase I _{Ks} current and are associated with QT interval shortening in dilated cardiomyopathy. <i>Cardiovascular Research</i> , 2013, 98, 496-503.	1.8	28
120	Suppression of persistent atrial fibrillation by genetic knockdown of caspase 3: a pre-clinical pilot study. <i>European Heart Journal</i> , 2013, 34, 147-157.	1.0	85
121	Mechanisms of zolpidem-induced long QT syndrome: acute inhibition of recombinant hERG K ⁺ channels and action potential prolongation in human cardiomyocytes derived from induced pluripotent stem cells. <i>British Journal of Pharmacology</i> , 2013, 168, 1215-1229.	2.7	13
122	Biological Heart Rate Reduction Through Genetic Suppression of G _i s Protein in the Sinoatrial Node. <i>Journal of the American Heart Association</i> , 2012, 1, .	1.6	15
123	Chest Pain, Shortness of Breath, and Palpitations Unmask an Unexpected Diagnosis. <i>Circulation</i> , 2012, 125, 843-846.	1.6	1
124	Novel electrophysiological properties of dronedarone: inhibition of human cardiac two-pore-domain potassium (K2P) channels. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2012, 385, 1003-1016.	1.4	43
125	Genetic suppression of atrial fibrillation using a dominant-negative ether-a-go-go-related gene mutant. <i>Heart Rhythm</i> , 2012, 9, 265-272.	0.3	61
126	Suppression of Atrial Fibrillation by Over-Expression of Connexin 43 in a Porcine Model. <i>Biophysical Journal</i> , 2012, 102, 675a.	0.2	0

#	ARTICLE	IF	CITATIONS
127	PKC-dependent activation of human K _{2P} 18.1 K ⁺ channels. <i>British Journal of Pharmacology</i> , 2012, 166, 764-773.	2.7	39
128	Identification and functional characterization of zebrafish K2P10.1 (TREK2) two-pore-domain K ⁺ channels. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2012, 1818, 33-41.	1.4	29
129	Identification and functional characterization of the novel human ether-a-go-go-related gene (hERG) R744P mutant associated with hereditary long QT syndrome 2. <i>Biochemical and Biophysical Research Communications</i> , 2012, 418, 830-835.	1.0	9
130	Inhibition of cardiac Kir2.1 channels by beta3 adrenoceptor antagonist SR 59230A. <i>Biochemical and Biophysical Research Communications</i> , 2012, 424, 315-320.	1.0	5
131	Regulation of apoptosis in cardiomyocytes by phosphorylation of the receptor tyrosine kinase EphA2 and protection by lithocholic acid. <i>British Journal of Pharmacology</i> , 2012, 167, 1563-1572.	2.7	23
132	Atrioventricular delay programming in cardiac resynchronization therapy devices: fixed or adaptive?. <i>Journal of Electrocardiology</i> , 2012, 45, 783-786.	0.4	1
133	Impaired ion channel function related to a common KCNQ1 mutation – Implications for risk stratification in long QT syndrome 1. <i>Gene</i> , 2012, 511, 26-33.	1.0	5
134	Enhancement of K2P2.1 (TREK1) background currents expressed in <i>Xenopus</i> oocytes by voltage-gated K ⁺ channel β subunits. <i>Life Sciences</i> , 2012, 91, 377-383.	2.0	18
135	Altered HCN4 Channel C-Linker Interaction is Associated with Familial Tachycardia-Bradycardia Syndrome and Atrial Fibrillation. <i>Biophysical Journal</i> , 2012, 102, 675a.	0.2	0
136	Electrophysiological findings in Fabry cardiomyopathy: mapping the maze of risk stratification. <i>Acta Cardiologica</i> , 2012, 67, 481-485.	0.3	1
137	Genetic suppression of G β s protein provides rate control in atrial fibrillation. <i>Basic Research in Cardiology</i> , 2012, 107, 265.	2.5	32
138	TASK1 (K _{2P} 3.1) K ⁺ channel inhibition by endothelin-1 is mediated through Rho kinase-dependent phosphorylation. <i>British Journal of Pharmacology</i> , 2012, 165, 1467-1475.	2.7	48
139	Initial experience with robotic navigation for catheter ablation of paroxysmal and persistent atrial fibrillation. <i>Journal of Electrocardiology</i> , 2012, 45, 95-101.	0.4	23
140	Biophysical Properties of the Kcnq1 S277I Mutation Linked to Hereditary Long Qt Syndrome with Phenotypic Variability. <i>Biophysical Journal</i> , 2011, 100, 197a.	0.2	0
141	The Novel cAMP-Insensitive HCN4-695X Mutation is Associated with Marked Sinus Bradycardia but Regular Autonomic Rate Control. <i>Biophysical Journal</i> , 2011, 100, 105a.	0.2	0
142	Biophysical properties of mutant KCNQ1 S277L channels linked to hereditary long QT syndrome with phenotypic variability. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2011, 1812, 488-494.	1.8	6
143	The pathology and treatment of cardiac arrhythmias: focus on atrial fibrillation. <i>Vascular Health and Risk Management</i> , 2011, 7, 193.	1.0	38
144	Dronedaron: current evidence for its safety and efficacy in the management of atrial fibrillation. <i>Drug Design, Development and Therapy</i> , 2011, 5, 27.	2.0	16

#	ARTICLE	IF	CITATIONS
145	Carvedilol targets human K _{2P} 3.1 (TASK1) K ⁺ leak channels. <i>British Journal of Pharmacology</i> , 2011, 163, 1099-1110.	2.7	38
146	Alternative splicing determines mRNA translation initiation and function of human K _{2P} 10.1 K ⁺ channels. <i>Journal of Physiology</i> , 2011, 589, 3709-3720.	1.3	34
147	Asymptomatic pulmonary vein stenosis after cryoballoon catheter ablation of paroxysmal atrial fibrillation. <i>Journal of Electrocardiology</i> , 2011, 44, 473-476.	0.4	37
148	hERG K ⁺ channel-associated cardiac effects of the antidepressant drug desipramine. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2011, 383, 119-139.	1.4	36
149	Antidepressant-induced Ubiquitination and Degradation of the Cardiac Potassium Channel hERG. <i>Journal of Biological Chemistry</i> , 2011, 286, 34413-34425.	1.6	40
150	Connexin 43 gene therapy prevents persistent atrial fibrillation in a porcine model. <i>Cardiovascular Research</i> , 2011, 92, 218-225.	1.8	143
151	Systemic Embolization and Myocardial Infarction due to Clinically Unrecognized Left Atrial Myxoma. <i>Case Reports in Medicine</i> , 2011, 2011, 1-3.	0.3	13
152	The human cardiac K _{2P} 3.1 (TASK-1) potassium leak channel is a molecular target for the class III antiarrhythmic drug amiodarone. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2010, 381, 261-270.	1.4	47
153	Multiple mechanisms of hERG liability: K ⁺ current inhibition, disruption of protein trafficking, and apoptosis induced by amoxapine. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2010, 381, 385-400.	1.4	33
154	Successful acute and long-term management of electrical storm in Brugada syndrome using orciprenaline and quinine/quinidine. <i>Clinical Research in Cardiology</i> , 2010, 99, 467-470.	1.5	61
155	Post-Transcriptional Control of Human Ether-a-go-go-Related Gene Potassium Channel Protein by β -Adrenergic Receptor Stimulation. <i>Molecular Pharmacology</i> , 2010, 78, 186-197.	1.0	20
156	cAMP Sensitivity of HCN Pacemaker Channels Determines Basal Heart Rate But Is Not Critical for Autonomic Rate Control. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2010, 3, 542-552.	2.1	66
157	Biophysical characterization of KCNQ1 P320 mutations linked to long QT syndrome 1. <i>Journal of Molecular and Cellular Cardiology</i> , 2010, 48, 230-237.	0.9	16
158	Multiple Mechanisms Contribute to Cardiotoxicity Observed with the Antidepressant Desipramine. <i>Biophysical Journal</i> , 2010, 98, 337a.	0.2	0
159	hERG: protein trafficking and potential for therapy and drug side effects. <i>Current Opinion in Drug Discovery & Development</i> , 2010, 13, 23-30.	1.9	16
160	Transcription profiling of HCN-channel isoforms throughout mouse cardiac development. <i>Basic Research in Cardiology</i> , 2009, 104, 621-629.	2.5	41
161	Selective noradrenaline reuptake inhibitor atomoxetine directly blocks hERG currents. <i>British Journal of Pharmacology</i> , 2009, 156, 226-236.	2.7	39
162	Biophysical properties of zebrafish ether- \tilde{A} -go-go related gene potassium channels. <i>Biochemical and Biophysical Research Communications</i> , 2009, 381, 159-164.	1.0	34

#	ARTICLE	IF	CITATIONS
163	Inhibition of cardiac hERG potassium channels by tetracyclic antidepressant mianserin. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2008, 378, 73-83.	1.4	17
164	Doxazosin induces apoptosis of cells expressing hERG K ⁺ channels. <i>European Journal of Pharmacology</i> , 2008, 579, 98-103.	1.7	23
165	Alternative Translation Initiation in Rat Brain Yields K2P2.1 Potassium Channels Permeable to Sodium. <i>Neuron</i> , 2008, 58, 859-870.	3.8	134
166	Kir2.x inward rectifier potassium channels are differentially regulated by adrenergic β 1A receptors. <i>Journal of Molecular and Cellular Cardiology</i> , 2008, 44, 84-94.	0.9	26
167	Aquaporin-1 Channel Function Is Positively Regulated by Protein Kinase C. <i>Journal of Biological Chemistry</i> , 2007, 282, 20933-20940.	1.6	74
168	Orange flavonoid hesperetin modulates cardiac hERG potassium channel via binding to amino acid F656. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2007, 17, 666-675.	1.1	37
169	Green tea flavonoid epigallocatechin-3-gallate (EGCG) inhibits cardiac hERG potassium channels. <i>Biochemical and Biophysical Research Communications</i> , 2007, 364, 429-435.	1.0	36
170	Activation of inwardly rectifying Kir2.x potassium channels by β 23-adrenoceptors is mediated via different signaling pathways with a predominant role of PKC for Kir2.1 and of PKA for Kir2.2. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2007, 375, 311-322.	1.4	26
171	Anticholinergic antiparkinson drug orphenadrine inhibits HERG channels: block attenuation by mutations of the pore residues Y652 or F656. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2007, 376, 275-284.	1.4	12
172	Skipping of Exon 1 in the KCNQ1 Gene Causes Jervell and Lange-Nielsen Syndrome. <i>Journal of Biological Chemistry</i> , 2006, 281, 35397-35403.	1.6	22
173	In vitro modulation of HERG channels by organochlorine solvent trichloromethane as potential explanation for proarrhythmic effects of chloroform. <i>Toxicology Letters</i> , 2006, 165, 156-166.	0.4	11
174	Regulation of cardiac inwardly rectifying potassium current IK1 and Kir2.x channels by endothelin-1. <i>Journal of Molecular Medicine</i> , 2006, 84, 46-56.	1.7	25
175	Atypical tetracyclic antidepressant maprotiline is an antagonist at cardiac hERG potassium channels. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2006, 373, 212-220.	1.4	16
176	Inhibition of cardiac HERG channels by grapefruit flavonoid naringenin: implications for the influence of dietary compounds on cardiac repolarisation. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2005, 371, 516-525.	1.4	36
177	Dominant-negative suppression by KCNQ1- β F339 potassium channels linked to Romano-Ward syndrome. <i>Cardiovascular Research</i> , 2005, 67, 487-497.	1.8	17
178	QTc Prolongation by Grapefruit Juice and Its Potential Pharmacological Basis. <i>Circulation</i> , 2005, 111, 835-838.	1.6	84
179	The Novel Antiarrhythmic Drug Dronedaron: Comparison with Amiodaron. <i>Cardiovascular Drug Reviews</i> , 2005, 23, 217-230.	4.4	75
180	Human cardiac inwardly rectifying current IKir2.2 is upregulated by activation of protein kinase A. <i>Cardiovascular Research</i> , 2004, 63, 520-527.	1.8	39

#	ARTICLE	IF	CITATIONS
181	Direct block of hERG potassium channels by the protein kinase C inhibitor bisindolylmaleimide I (GF109203X). <i>Cardiovascular Research</i> , 2004, 64, 467-476.	1.8	49
182	Inhibition of cardiac HERG currents by the DNA topoisomerase II inhibitor amsacrine: mode of action. <i>British Journal of Pharmacology</i> , 2004, 142, 485-494.	2.7	28
183	Radiation therapy-induced electrical reset of an implantable cardioverter defibrillator device located outside the irradiation field. <i>Journal of Electrocardiology</i> , 2004, 37, 73-74.	0.4	35
184	Adrenergic regulation of the rapid component of the cardiac delayed rectifier potassium current, IKr, and the underlying hERG ion channel. <i>Basic Research in Cardiology</i> , 2004, 99, 279-87.	2.5	64
185	Activation of cardiac human ether-a-go-go related gene potassium currents is regulated by β 1A-adrenoceptors. <i>Journal of Molecular Medicine</i> , 2004, 82, 826-837.	1.7	29
186	Inhibition of human ether-a-go-go-related gene potassium channels by α 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2004, 369, 462-472.	1.4	45
187	Inhibition of cardiac HERG potassium channels by the atypical antidepressant trazodone. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2004, 370, 146-56.	1.4	45
188	Class Ia anti-arrhythmic drug ajmaline blocks HERG potassium channels: mode of action. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2004, 370, 423-435.	1.4	46
189	Modulation of HERG potassium channel function by drug action. <i>Annals of Medicine</i> , 2004, 36, 41-46.	1.5	7
190	Inhibition of cloned HERG potassium channels by the antiestrogen tamoxifen. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2003, 368, 41-48.	1.4	42
191	Human β 3-adrenoreceptors couple to KvLQT1/MinK potassium channels in <i>Xenopus</i> oocytes via protein kinase C phosphorylation of the KvLQT1 protein. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2003, 368, 119-126.	1.4	27
192	Drug binding to aromatic residues in the HERG channel pore cavity as possible explanation for acquired Long QT syndrome by antiparkinsonian drug budipine. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2003, 368, 404-414.	1.4	39
193	The antipsychotic drug chlorpromazine inhibits HERG potassium channels. <i>British Journal of Pharmacology</i> , 2003, 139, 567-574.	2.7	64
194	Acute effects of dronedarone on both components of the cardiac delayed rectifier K ⁺ current, HERG and KvLQT1/minK potassium channels. <i>British Journal of Pharmacology</i> , 2003, 140, 996-1002.	2.7	45
195	Regulation of HERG potassium channel activation by protein kinase C independent of direct phosphorylation of the channel protein. <i>Cardiovascular Research</i> , 2003, 59, 14-26.	1.8	63
196	Defective protein trafficking in hERG-associated hereditary long QT syndrome (LQT2): molecular mechanisms and restoration of intracellular protein processing. <i>Cardiovascular Research</i> , 2003, 60, 235-241.	1.8	80
197	The Antidepressant Drug Fluoxetine Is an Inhibitor of Human Ether-A-Go-Go-Related Gene (HERG) Potassium Channels. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 300, 543-548.	1.3	117
198	Human Cardiac Inwardly-Rectifying K ⁺ Channel Kir 2.1b Is Inhibited by Direct Protein Kinase C-Dependent Regulation in Human Isolated Cardiomyocytes and in an Expression System. <i>Circulation</i> , 2002, 106, 1493-1499.	1.6	62

#	ARTICLE	IF	CITATIONS
199	Bertosamil blocks HERG potassium channels in their open and inactivated states. <i>British Journal of Pharmacology</i> , 2002, 137, 221-228.	2.7	20
200	The Antiarrhythmic Drug BRL-32872. <i>Cardiovascular Drug Reviews</i> , 2002, 20, 111-120.	4.4	4
201	Novel characteristics of a misprocessed mutant HERG channel linked to hereditary long QT syndrome. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2000, 279, H1748-H1756.	1.5	88
202	Functional Coupling of Human β -Adrenoreceptors to the KvLQT1/MinK Potassium Channel. <i>Journal of Biological Chemistry</i> , 2000, 275, 26743-26747.	1.6	22
203	Deletion of Protein Kinase A Phosphorylation Sites in the HERG Potassium Channel Inhibits Activation Shift by Protein Kinase A. <i>Journal of Biological Chemistry</i> , 1999, 274, 27457-27462.	1.6	108
204	Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1999, 359, 212-219.	1.4	94
205	HERG Potassium Channel Activation Is Shifted by Phorbol Esters via Protein Kinase A-dependent Pathways. <i>Journal of Biological Chemistry</i> , 1998, 273, 25285-25291.	1.6	84